| 【Fixed Income Research】GRNLGR – Prefer short-end |
| 【Fixed Income Research】BEDUUS: Upgrade to Buy at 93.8, as controlling shareholder’s privatization offer reflects willingness to pay |
| 【Company Research】HUTCHMED (13 HK) – FDA raised the bar for the approval of surufatinib |
| 【Company Research】Bilibili (BILI US) – Factoring in epidemic impact |
| 【Company Research】Bank of Changsha (601577 CH) – FY21&1Q22 review: strong growth with good cost control |
| 【Company Research】Bank of Shanghai (601229 CH) – 1Q22 review: results in line, sufficient provision for headwind |
| 【Company Research】Tencent (700 HK) – Challenges yet over, but LT fundamentals intact |
| 【Company Research】China Construction Bank (939 HK) – 1Q22 review: results in line, propose to issue TLAC instruments in late FY22 |
| 【Company Research】SPDB (600000 CH) – FY21&1Q22 review: still waiting for the turning point |
| 【Company Research】PSBC (1658 HK) – 1Q22 review: strong growth beats our expectation |
公司地址：香港中環花園道三號冠君大廈45-46樓
電話：（852） 3900-0888 傳真：（852） 3761-8788
招銀國際版權所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
